Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06026514
Other study ID # CIR 355
Secondary ID
Status Recruiting
Phase Phase 1
First received
Last updated
Start date September 18, 2023
Est. completion date June 2025

Study information

Verified date November 2023
Source National Institute of Allergy and Infectious Diseases (NIAID)
Contact Kawsar Talaat, MD
Phone 410-336-9164
Email ktalaat@jhu.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This Phase 1 clinical trial will evaluate the safety and immunogenicity of an intranasal vaccine candidate, a recombinant, live-attenuated, bovine/human parainfluenza virus vector vaccine expressing the 6-P prefusion-stabilized version of the SARS-CoV-2 spike protein.


Description:

The proposed study is a single center, open label study to be conducted at the Johns Hopkins Bloomberg School of Public Health, Center for Immunization Research (CIR) in Baltimore, MD. Participants will be followed for 12 months after the first immunization, so the duration of study participation will be 12 months after receipt of initial vaccination. Approximately 30 subjects will be enrolled in a rolling fashion to receive 2 doses of the B/HPIV3/S-6P vaccine intranasally 56 days apart. Participants who are enrolled and receive the first vaccine dose will not be replaced, even in the event they are ineligible or unable to take the second dose. Up to 60 subjects will be consented to ensure that 30 subjects are eligible for enrollment and vaccination. Volunteers will be enrolled in a staggered fashion: Group 1: Up to 5 volunteers will be enrolled and vaccinated. Group 2: Up to 10 volunteers will be enrolled and vaccinated. Group 3: The remaining volunteers (up to 15) will be enrolled and vaccinated.


Recruitment information / eligibility

Status Recruiting
Enrollment 30
Est. completion date June 2025
Est. primary completion date November 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 50 Years
Eligibility Inclusion Criteria: 1. Nonpregnant adults between 18 years and 50 years of age, inclusive. 2. General good health, without significant medical illness, physical examination findings, or significant laboratory abnormalities as determined by the investigator. 3. Demonstrates comprehension of the protocol procedures and knowledge of the trial by passing a written comprehension examination (passing grade > 70%). 4. Available for the duration of the trial. 5. Willingness to participate in the study and cooperate with the study procedures as evidenced by signing the informed consent document. 6. Persons of childbearing potential must have used effective birth control methods for at least one month prior to vaccination, and agree to continue with 'per label/fully effective use' for the chosen method for the duration of the study (30 days prior to first vaccination until 12 months after first vaccination), from amongst these: - pharmacologic/hormonal contraceptives, including oral, parenteral, subcutaneous, and transcutaneous delivery; - condoms or diaphragm with spermicide; - intrauterine device; - absolute abstinence from heterosexual intercourse as a matter of normal preferred lifestyle; - or must be surgically sterile or have documented menopause, having had no menses at all for at least one full year. All persons of childbearing potential must provide samples for urine and serum pregnancy testing prior to enrollment and prior to vaccination. Pregnancy risk assessment and pregnancy prevention counseling will occur at each point of contact. 7. Willingness to refrain from blood donation during participation in the study and for at least 1 year after receiving the second dose of vaccine. 8. Willingness to refrain from receiving vaccines or other investigational products during the first 90 days of the study after enrollment. Exclusion Criteria: 1. Pregnancy as determined by a positive human choriogonadotropin (ßHCG) test in a person of reproductive capacity. 2. Currently breastfeeding. 3. Evidence of clinically significant neurologic, cardiac, pulmonary, hepatic, rheumatologic, autoimmune, or renal disease by history, physical examination, electrocardiogram (EKG), and/or laboratory studies. 4. Behavioral or cognitive impairment or psychiatric disease that in the opinion of the investigator affects the ability of the subject to understand and cooperate with the study protocol. 5. A history of asthma within the past 5 years, or a current diagnosis of asthma or reactive airway disease associated with exercise, seasonal hay fever or allergic rhinitis. 6. Presence of any febrile illness or symptoms suggestive of a respiratory infection within 2 weeks prior to inoculation. 7. Use of systemic or nasal steroid preparations or immunosuppressive drugs within 30 days prior to vaccination. Topical steroid preparations are permitted. 8. Inhaled bronchodilator or inhaled steroid use within the last year or use after upper respiratory tract infections within the last 5 years. 9. Current or past (in the last 4 weeks) use of intranasal medications (including steroids, decongestants, or hormonal medications), or planning to use them within 28 days of study vaccination. 10. Evidence of current alcohol or illicit drug abuse or addiction. 11. Other condition that in the opinion of the investigator would jeopardize the safety or rights of a subject participating in the trial or would render the subject unable to comply with the protocol. 12. Positive ELISA and confirmatory tests for human immunodeficiency virus (HIV). 13. Positive ELISA and confirmatory test (e.g., recombinant immunoblot assay) for hepatitis C virus (HCV). 14. Positive hepatitis B virus surface antigen (HBsAg) by ELISA. 15. Known immunodeficiency syndrome. 16. Receipt of a live vaccine within 4 weeks or a killed vaccine within 2 weeks prior to receipt of the study vaccine or planned receipt within 90 days after vaccination. (Exception, influenza vaccine may be obtained more than 2 weeks after or prior to the study vaccine). 17. History of a surgical splenectomy. 18. Receipt of blood or blood-derived products (including immunoglobulin [Ig]) within 6 months prior to study inoculation. 19. Has participated in another investigational study involving any investigational product within 30 days, or 5 half-lives, whichever is longer, before the first vaccine administration. 20. Body mass index (BMI) < 18.5 or >40. 21. Any significant abnormality of the nose or nasopharynx, including recurrent epistaxis and including nasal or sinus surgery. 22. History of Bell's palsy. 23. Has a confirmed SARS-CoV-2 infection or COVID-19 vaccine/booster within 16 weeks prior to enrollment. 24. Unwillingness to have nasopharyngeal (NP) or blood samples saved for future respiratory virus research. 25. Pulmonary function test (PFT) testing for FVC, FEV1, FEV1% and PEF of <80 or incentive spirometer value < normal parameters based on gender, age, and height.

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
B/HPIV3/S-6P
Intranasal vaccine.

Locations

Country Name City State
United States Johns Hopkins Bloomberg School of Public Health Baltimore Maryland

Sponsors (3)

Lead Sponsor Collaborator
National Institute of Allergy and Infectious Diseases (NIAID) Johns Hopkins Bloomberg School of Public Health, National Institutes of Health (NIH)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary To determine the frequency of vaccine-related solicited adverse events (AEs) Summary and line listing of individual clinical solicited of the frequency of solicited AEs During study days 0 to 28 and 56 to 84 (28 days after each dose)
Primary To determine the frequency of vaccine-related unsolicited AEs Summary and line listing of individual clinical solicited of the frequency of unsolicited AEs During study days 0 to 28 and 56 to 84 (28 days after each dose)
Primary To determine the frequency of vaccine-related lower respiratory illness Summary and line listing of individual clinical solicited of the frequency of vaccine-related lower respiratory illness During study days 0 to 28 and 56 to 84 (28 days after each dose)
Primary Vaccine virus shedding on 1 or more days As assessed by culture, or rRT-PCR On Days 4, 7, and 10, and 60, 63, and 66
Primary Evidence of a >4-fold rise in HPIV3 antibody titers Using PRNT60 or ELISA When comparing pre-vaccination titers day 29, 56 or 90
Secondary Rise in serum neutralizing antibody titer to SARS-CoV-2 S protein Will be measured by ELISA and neutralization assay On days 63, 70, 84, 180, 360
See also
  Status Clinical Trial Phase
Terminated NCT04555096 - A Trial of GC4419 in Patients With Critical Illness Due to COVID-19 Phase 2
Completed NCT04593641 - This is a Phase 1 Study to Evaluate the Safety,Tolerability and Virology of CT P59 in Patients With Mild Symptoms of Symptoms of Coronavirus Disease (COVID-19) Phase 1
Recruiting NCT05200754 - Trial With or Without Infusion of SARS-CoV-2 Antibody Containing Plasma in High-Risk Patients With COVID-19 Phase 2
Completed NCT04583995 - A Study Looking at the Effectiveness, Immune Response, and Safety of a COVID-19 Vaccine in Adults in the United Kingdom Phase 3
Recruiting NCT06255860 - SARS-COV-2 Reinfection and Multisystem Inflammatory Syndrome in Children (MIS-C) Risk: Matched Case-control Study
Recruiting NCT04516811 - Therapeutic Use of Convalescent Plasma in the Treatment of Patients With Moderate to Severe COVID-19 Phase 3
Recruiting NCT05012826 - Osteopathy and Physiotherapy Compared to Physiotherapy Alone on Fatigue and Functional Status in Long COVID N/A
Completed NCT05007236 - Study to Evaluate the Efficacy and Safety of Oral RP7214, a DHODH Inhibitor, in Patients With Symptomatic Mild COVID-19 Infection. Phase 2
Completed NCT05523739 - Safety and Efficacy Study of STI-1558 in Healthy Adults and SARS-CoV-2-Positive Patients Phase 1
Suspended NCT04738136 - Safety, Tolerability and Efficacy Of S-1226 in Moderate Severity Covid-19 Bronchiolitis/Pneumonia Phase 2
Recruiting NCT04584658 - Dysphagia and Dysphonia Outcomes in SARS CoV-2 (COVID-19) Infection (DYADS Study)
Recruiting NCT04547114 - Breath Analysis for SARS-CoV-2 in Infected and Healthy Subjects
Completed NCT05119348 - Transmission of Coronavirus Disease 2019 (COVID19) in Crowded Environments N/A
Completed NCT05096962 - COVID-19: SARS-CoV-2-CZ-PREVAL-II Study
Recruiting NCT04534400 - Automated Quantification of Radiologic Pulmonary Alteration During Acute Respiratory Failure
Completed NCT04527354 - Pilot Study to Assess Efficacy and Safety of Treamid in the Rehabilitation of Patients After COVID-19 Pneumonia Phase 2
Completed NCT04583982 - ImmuneSense™ COVID-19 Study
Completed NCT05077176 - Phase 3 Booster Vaccination Against COVID-19 Phase 3
Completed NCT05584189 - COVID-19 MP Biomedicals Rapid SARS-CoV-2 Antigen Test Usability N/A
Completed NCT04600999 - Clinical Trial of Favipiravir Treatment of Patients With COVID-19 Phase 3